JP2017061570A5 - - Google Patents

Download PDF

Info

Publication number
JP2017061570A5
JP2017061570A5 JP2016249307A JP2016249307A JP2017061570A5 JP 2017061570 A5 JP2017061570 A5 JP 2017061570A5 JP 2016249307 A JP2016249307 A JP 2016249307A JP 2016249307 A JP2016249307 A JP 2016249307A JP 2017061570 A5 JP2017061570 A5 JP 2017061570A5
Authority
JP
Japan
Prior art keywords
immunotherapeutic composition
cancer
seq
composition
yeast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016249307A
Other languages
English (en)
Japanese (ja)
Other versions
JP6309607B2 (ja
JP2017061570A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017061570A publication Critical patent/JP2017061570A/ja
Publication of JP2017061570A5 publication Critical patent/JP2017061570A5/ja
Application granted granted Critical
Publication of JP6309607B2 publication Critical patent/JP6309607B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016249307A 2011-03-17 2016-12-22 酵母−ブラキュリ免疫治療組成物 Active JP6309607B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161453656P 2011-03-17 2011-03-17
US61/453,656 2011-03-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013558234A Division JP6068368B2 (ja) 2011-03-17 2012-03-19 酵母−ブラキュリ免疫治療組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018046148A Division JP6580733B2 (ja) 2011-03-17 2018-03-14 酵母−ブラキュリ免疫治療組成物

Publications (3)

Publication Number Publication Date
JP2017061570A JP2017061570A (ja) 2017-03-30
JP2017061570A5 true JP2017061570A5 (https=) 2017-05-18
JP6309607B2 JP6309607B2 (ja) 2018-04-11

Family

ID=46831122

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013558234A Active JP6068368B2 (ja) 2011-03-17 2012-03-19 酵母−ブラキュリ免疫治療組成物
JP2016249307A Active JP6309607B2 (ja) 2011-03-17 2016-12-22 酵母−ブラキュリ免疫治療組成物
JP2018046148A Active JP6580733B2 (ja) 2011-03-17 2018-03-14 酵母−ブラキュリ免疫治療組成物
JP2019155138A Pending JP2019199484A (ja) 2011-03-17 2019-08-28 酵母−ブラキュリ免疫治療組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013558234A Active JP6068368B2 (ja) 2011-03-17 2012-03-19 酵母−ブラキュリ免疫治療組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018046148A Active JP6580733B2 (ja) 2011-03-17 2018-03-14 酵母−ブラキュリ免疫治療組成物
JP2019155138A Pending JP2019199484A (ja) 2011-03-17 2019-08-28 酵母−ブラキュリ免疫治療組成物

Country Status (19)

Country Link
US (5) US9198941B2 (https=)
EP (2) EP3238731B1 (https=)
JP (4) JP6068368B2 (https=)
KR (1) KR102046449B1 (https=)
CN (1) CN103648513B (https=)
AU (3) AU2012228937B2 (https=)
BR (1) BR112013023456B1 (https=)
CA (1) CA2835475C (https=)
DK (1) DK2685995T3 (https=)
ES (1) ES2627979T3 (https=)
HK (1) HK1245649A1 (https=)
HU (1) HUE033491T2 (https=)
IL (1) IL228421B (https=)
MX (1) MX350661B (https=)
PL (1) PL2685995T3 (https=)
PT (1) PT2685995T (https=)
RU (2) RU2690180C2 (https=)
SG (2) SG10201601913RA (https=)
WO (1) WO2012125998A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
EA028659B1 (ru) 2011-02-12 2017-12-29 Глоубиммьюн, Инк. Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
RU2690180C2 (ru) 2011-03-17 2019-05-31 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей с brachyury
BR112013032381B1 (pt) 2011-06-14 2021-01-12 Globeimmune, Inc. composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta
KR102049928B1 (ko) 2011-08-17 2019-11-28 글로브이뮨 효모-muc1 면역요법 조성물 및 그 용도
SG11201408652SA (en) 2012-06-26 2015-01-29 Biodesix Inc Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
WO2014043518A1 (en) * 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
MX374829B (es) * 2013-03-19 2025-03-06 Globeimmune Inc Composición a base de levadura para usarse para tratar cordoma.
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
US9725494B2 (en) * 2013-05-17 2017-08-08 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble CD27 (sCD27) and the use thereof
US10226522B2 (en) 2013-08-30 2019-03-12 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
US10799567B2 (en) 2014-04-11 2020-10-13 Globeimmune, Inc. Yeast-based immunotherapy and type I interferon sensitivity
KR102193635B1 (ko) 2015-01-09 2020-12-21 이투빅스 코포레이션 복합 면역요법을 위한 방법 및 조성물
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
WO2017023840A1 (en) * 2015-08-03 2017-02-09 Globeimmune, Inc. Modified yeast-brachyury immunotherapeutic compositions
EP4137150A1 (en) * 2015-08-03 2023-02-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
JP2019513021A (ja) 2016-03-24 2019-05-23 ナントセル,インコーポレイテッド ネオエピトープ提示のための配列の配置および配列
CA3026342A1 (en) * 2016-06-03 2017-12-07 Etubics Corporation Compositions and methods for tumor vaccination using prostate cancer-associated antigens
US11571446B2 (en) 2016-11-18 2023-02-07 Sanford Bumham Prebys Medical Discovery Institute Gut microbiota and treatment of cancer
IL314202B1 (en) 2017-04-24 2026-04-01 Nantcell Inc Neoepitope vectors and methods for them
EP3668538A4 (en) * 2017-08-15 2021-06-16 NantCell, Inc. HANK-CETUXIMAB COMBINATIONS AND PROCEDURES
WO2019222073A1 (en) 2018-05-15 2019-11-21 Globeimmune, Inc. Lysates of recombinant yeast for inducing cellular immune responses
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1036329A (en) 1908-11-19 1912-08-20 Edison Inc Thomas A Phonograph-reproducer.
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
WO2002039951A2 (en) 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
CN102370974B (zh) 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
KR20080043775A (ko) 2005-07-11 2008-05-19 글로브이뮨 표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
WO2007092792A2 (en) 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
BRPI0709340A2 (pt) * 2006-03-27 2013-04-16 Globeimmune, Inc. mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
AU2008214029B2 (en) 2007-02-02 2014-01-30 Globelmmune, Inc. Methods for producing yeast-based vaccines
EP2125868B1 (en) 2007-02-28 2015-06-10 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
EP2134358A1 (en) 2007-03-19 2009-12-23 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
WO2009042642A2 (en) 2007-09-24 2009-04-02 President And Fellows Of Harvard College Compositions and methods for the treatment and prevention of ulcerative colitis and colon cancer
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン,インコーポレイテッド 慢性c型肝炎ウイルス感染の免疫療法
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
KR101781966B1 (ko) * 2009-04-17 2017-09-27 글로브이뮨 암에 대한 병용 면역요법 조성물 및 방법
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
US20130121964A1 (en) 2010-03-14 2013-05-16 Globeimmune, Inc. Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy
WO2012019127A2 (en) * 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
EA028659B1 (ru) 2011-02-12 2017-12-29 Глоубиммьюн, Инк. Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
RU2690180C2 (ru) 2011-03-17 2019-05-31 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей с brachyury
BR112013032381B1 (pt) 2011-06-14 2021-01-12 Globeimmune, Inc. composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta
KR102049928B1 (ko) 2011-08-17 2019-11-28 글로브이뮨 효모-muc1 면역요법 조성물 및 그 용도

Similar Documents

Publication Publication Date Title
JP2017061570A5 (https=)
RU2017116350A (ru) Иммунотерапевтические композиции на основе дрожжей с brachyury
JP2015096557A5 (https=)
JP2016128513A5 (https=)
JP2020176156A (ja) Toll様受容体モジュレーターの固体形態
HRP20190774T1 (hr) Kombinacija anti-lag-3 antitijela i anti-pd-1 antitijela za liječenje tumora
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
RU2019102009A (ru) Специфические антитела к pd-l1 и способы их применения
PH12021552476A1 (en) Compositions and methods for preparing t cell compositions and uses thereof
JP2010529026A5 (https=)
EP3308798A3 (en) Polypeptides and antibodies for treating hbv infection and related diseases
MX348577B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
WO2012065055A3 (en) Fusion proteins for hiv therapy
RU2015155821A (ru) Вакцины против малярии
NZ760065A (en) Methods of treating cancers using pd-1 axis binding antagonists and taxanes
HRP20170468T1 (hr) Bispecifična protutijela protiv baff i protiv il-17
JP2016520082A5 (https=)
AR078377A1 (es) Anticuerpos anti-vegf-c (factor de crecimiento endotelial anti-vascular aislado c) y sus metodos de uso
JP2014523878A5 (https=)
EA201591213A1 (ru) Вакцины против вируса гепатита b
JP2015533376A5 (https=)
RU2017103679A (ru) Способ ингибирования внутриклеточного активированного ras с помощью интакного антитела иммуноглобулинового типа, обладающего способностью к проникновению в цитозоль, и его применение
JP2015530989A5 (https=)
RU2018130986A (ru) Антитела к jagged и способы их применения
MX2022005086A (es) Anticuerpos anti-cd73 inmunomoduladores y usos de estos.